Identification of Cost-Saving Opportunities for the Use of Antithrombin III in Adult and Pediatric Patients.

ABSTRACT: Thrombate III is a human plasma-derived antithrombin III (AT-III) often utilized in patients on extracorporeal membrane oxygenation (ECMO) with suspected AT-III-mediated heparin resistance. It is supplied as 500-U and 1000-U vials, costing US$4.66 per unit. Literature is limited in describing the clinical value of AT-III in relation to its high cost. The primary objective was to determine conditions of use and associated cost of potentially unnecessary utilization of AT-III at The Johns Hopkins Hospital. Secondary objectives included evaluating the effect of AT-III on anticoagulation parameters and the overall cost utilized and wasted on AT-III. A retrospective cohort study was performed. The primary end point was the total cost associated with potentially unnecessary utilization of AT-III

SUBMITTER: Ciolek A 

PROVIDER: S-EPMC6714634 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature